H.C. Wainwright raised the firm’s price target on PDS Biotechnology (PDSB) to $15 from $13 and keeps a Buy rating on the shares. The firm is increasing its view of the probability of success for PDS0101 in head and neck cancer to 65% from 40% following the most recent median overall survival data from the VERSATILE-002 study, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PDSB:
- PDS Biotechnology reports Q3 EPS (19c), consensus (20c)
- PDS Biotechnology Announces $11.1M Securities Purchase Agreement
- PDS Biotechnology announces up to $11.1M registered direct offering
- PDS Biotechnology Announces Positive Data at Cancer Meeting
- PDS Biotechnology announces data on activity of PDS0101, PDS01ADC